Search

Your search keyword '"Abati, Andrea"' showing total 20 results
Start Over Author "Abati, Andrea" Search Limiters Available in Library Collection
20 results on '"Abati, Andrea"'

7. Human Melanoma Metastases Demonstrate Nonstochastic Site-Specific Antigen Heterogeneity That Correlates with T-cell Infiltration

Author

Bartlett, Edmund K., primary, Fetsch, Patricia A., additional, Filie, Armando C., additional, Abati, Andrea, additional, Steinberg, Seth M., additional, Wunderlich, John R., additional, White, Donald E., additional, Stephens, Daniel J., additional, Marincola, Francesco M., additional, Rosenberg, Steven A., additional, and Kammula, Udai S., additional

Published
2014
Full Text
View/download PDF

10. Evaluation of Prime/Boost Regimens Using Recombinant Poxvirus/Tyrosinase Vaccines for the Treatment of Patients with Metastatic Melanoma

Author

Lindsey, Kimberly R., primary, Gritz, Linda, additional, Sherry, Richard, additional, Abati, Andrea, additional, Fetsch, Patricia A., additional, Goldfeder, Lisa C., additional, Gonzales, Monica I., additional, Zinnack, Kimberly A., additional, Rogers-Freezer, Linda, additional, Haworth, Leah, additional, Mavroukakis, Sharon A., additional, White, Donald E., additional, Steinberg, Seth M., additional, Restifo, Nicholas P., additional, Panicali, Dennis L., additional, Rosenberg, Steven A., additional, and Topalian, Suzanne L., additional

Published
2006
Full Text
View/download PDF

11. High incidence of occult leptomeningeal disease detected by flow cytometry in newly diagnosed aggressive B-cell lymphomas at risk for central nervous system involvement: the role of flow cytometry versus cytology

Author

Hegde, Upendra, primary, Filie, Armando, additional, Little, Richard F., additional, Janik, John E., additional, Grant, Nicole, additional, Steinberg, Seth M., additional, Dunleavy, Kieron, additional, Jaffe, Elaine S., additional, Abati, Andrea, additional, Stetler-Stevenson, Maryalice, additional, and Wilson, Wyndham H., additional

Published
2005
Full Text
View/download PDF

12. Sequential gene profiling of basal cell carcinomas treated with imiquimod in a placebo-controlled study defines the requirements for tissue rejection

Author

Panelli, Monica C, Stashower, Mitchell E, Slade, Herbert B, Smith, Kina, Norwood, Christopher, Abati, Andrea, Fetsch, Patricia, Filie, Armando, Walters, Shelley-Ann, Astry, Calvin, Aricó, Eleonora, Zhao, Yingdong, Selleri, Silvia, Wang, Ena, and Marincola, Francesco M

Subjects
Imiquimod, Research, CD8 Antigens, Gene Expression Profiling, Interferon-alpha, Antineoplastic Agents, Polymerase Chain Reaction, CD56 Antigen, Gene Expression Regulation, Neoplastic, Placebos, Interferon-gamma, Carcinoma, Basal Cell, Aminoquinolines, Humans, RNA, Messenger, Genes, Neoplasm
Abstract

An analysis of basal cell carcinoma subjected to local application of imiquimod revealed that most transcripts stimulated by imiquimod involve the activation of cellular innate and adaptive immune-effector mechanisms., Background Imiquimod is a Toll-like receptor-7 agonist capable of inducing complete clearance of basal cell carcinoma (BCC) and other cutaneous malignancies. We hypothesized that the characterization of the early transcriptional events induced by imiquimod may provide insights about immunological events preceding acute tissue and/or tumor rejection. Results We report a paired analysis of adjacent punch biopsies obtained pre- and post-treatment from 36 patients with BCC subjected to local application of imiquimod (n = 22) or vehicle cream (n = 14) in a blinded, randomized protocol. Four treatments were assessed (q12 applications for 2 or 4 days, or q24 hours for 4 or 8 days). RNA was amplified and hybridized to 17.5 K cDNA arrays. All treatment schedules similarly affected the transcriptional profile of BCC; however, the q12 × 4 days regimen, associated with highest effectiveness, induced the most changes, with 637 genes unequivocally stimulated by imiquimod. A minority of transcripts (98 genes) confirmed previous reports of interferon-α involvement. The remaining 539 genes portrayed additional immunological functions predominantly involving the activation of cellular innate and adaptive immune-effector mechanisms. Importantly, these effector signatures recapitulate previous observations of tissue rejection in the context of cancer immunotherapy, acute allograft rejection and autoimmunity. Conclusion This study, based on a powerful and reproducible model of cancer eradication by innate immune mechanisms, provides the first insights in humans into the early transcriptional events associated with immune rejection. This model is likely representative of constant immunological pathways through which innate and adaptive immune responses combine to induce tissue destruction.

Published
2007

15. Characteristics of nine newly derived mesothelioma cell lines

Author

Pass, Harvey I., primary, Stevens, Emily J., additional, Oie, Herbert, additional, Tsokos, Maria G., additional, Abati, Andrea D., additional, Fetsch, Patricia A., additional, Mew, Daphne J.Y., additional, Pogrebniak, Helen W., additional, and Matthews, Wilbert J., additional

Published
1995
Full Text
View/download PDF

16. The multidrug-resistant phenotype associated with overexpression of the new ABC half-transporter, MXR (ABCG2)

Author

Litman, Thomas, Brangi, Mariafiorella, Hudson, Eric, Fetsch, Patricia, Abati, Andrea, Ross, Douglas D., Miyake, Keisuke, Resau, James H., and Bates, Susan E.

Abstract

Mechanisms of drug resistance other than P-glycoprotein are of increasing interest as the list of newly identified members of the ABC transport family has grown. We sought to characterize the phenotype of the newly discovered ABC transporter encoded by the mitoxantrone resistance gene, MXR, also known as ABCP1 or BCRP. The pharmacodynamics of mitoxantrone and 12 other fluorescent drugs were evaluated by confocal microscopy in four multidrug-resistant human colon (S1) and breast (MCF-7) cancer cell lines. We utilized two sublines, MCF-7 AdVp3000 and S1-M1-80, and detected overexpression of MXR by PCR, immunoblot assay and immunohistochemistry. These MXR overexpressing sublines were compared to cell lines with P-glycoprotein- and MRP-mediated resistance. High levels of cross-resistance were observed for mitoxantrone, the anthracyclines, bisantrene and topotecan. Reduced levels of mitoxantrone, daunorubicin, bisantrene, topotecan, rhodamine 123 and prazosin were observed in the two sublines with high MXR expression. Neither the P-glycoprotein substrates vinblastine, paclitaxel, verapamil and calcein-AM, nor the MRP substrate calcein, were extruded from MCF-7 AdVp3000 and S1-M1-80 cells. Thus, the multidrug-resistant phenotype due to MXR expression is overlapping with, but distinct from, that due to P-glycoprotein. Further, cells that overexpress the MXR protein seem to be more resistant to mitoxantrone and topotecan than cells with P-glycoprotein-mediated multidrug resistance. Our studies suggest that the ABC half-transporter, MXR, is a potent, new mechanism for conferring multiple drug resistance. Definition of its mechanism of transport and its role in clinical oncology is required.

Published
2000
Full Text
View/download PDF

17. Engraftment of MDR1and NeoR Gene-Transduced Hematopoietic Cells After Breast Cancer Chemotherapy

Author

Moscow, Jeffrey A., Huang, Hui, Carter, Charles, Hines, Kenneth, Zujewski, JoAnne, Cusack, Georgie, Chow, Cathy, Venzon, David, Sorrentino, Brian, Chiang, Yawen, Goldspiel, Barry, Leitman, Susan, Read, Elizabeth J., Abati, Andrea, Gottesman, Michael M., Pastan, Ira, Sellers, Stephanie, Dunbar, Cynthia, and Cowan, Kenneth H.

Abstract

To determine whether the multidrug resistance gene MDR1could act as a selectable marker in human subjects, we studied engraftment of peripheral blood progenitor cells (PBPCs) transduced with either MDR1or the bacterial NeoR gene in six breast cancer patients. This study differed from previous MDR1gene therapy studies in that patients received only PBPCs incubated in retroviral supernatants (no nonmanipulated PBPCs were infused), transduction of PBPCs was supported with autologous bone marrow stroma without additional cytokines, and a control gene (NeoR) was used for comparison with MDR1. Transduced PBPCs were infused after high-dose alkylating agent therapy and before chemotherapy with MDR-substrate drugs. We found that hematopoietic reconstitution can occur using only PBPCs incubated ex vivo, that theMDR1gene product may play a role in engraftment, and that chemotherapy may selectively expand MDR1gene-transduced hematopoietic cells relative to NeoR transduced cells in some patients.

Published
1999
Full Text
View/download PDF

18. Correspondence re: Bryant-Greenwood P, Sorbara L, Filie AC, Little R, Yarchoan R, Wilson W, Raffeld M, Abati A. Infection of mesothelial cells with human herpes virus 8 in human immunodeficiency virus-infected patients with Kaposi's sarcoma, Castleman's disease, and recurrent pleural effusions. Mod pathol 2003;16:145-53.

Author

Ascoli, Valeria, Abati, Andrea, Yarchoan, Robert, Sorbara, Lynn, Filie, Armando C., Little, Richard, Wilson, Wyndham, Raffeld, Mark, and Bryant-Greenwood, Peter

Published
2003
Full Text
View/download PDF

20. Granulocytic invasion of the central nervous system after hematopoietic stem cell transplantation for systemic lupus erythematosus.

Author

Muraro PA, Nikolov NP, Butman JA, Abati A, Gea-Banacloche J, Gress R, Lipsky P, Illei G, and Pavletic S

Subjects
Adrenal Cortex Hormones therapeutic use, Adult, Central Nervous System Diseases drug therapy, Hematopoietic Stem Cell Mobilization, Humans, Leukocyte Count, Male, Methylprednisolone therapeutic use, Neutrophils, Central Nervous System Diseases blood, Granulocytes pathology, Hematopoietic Stem Cell Transplantation adverse effects, Lupus Erythematosus, Systemic therapy
Abstract

We report on the likely mechanism of an exacerbation of neurological symptoms developed during immune reconstitution after autologous non-myeloablative hematopoietic stem cell transplantation in a 33-year-old man with systemic lupus erythematosus- associated recurrent transverse myelitis. Cerebrospinal fluid examination revealed prominent neutrophilic pleocytosis and no evidence of infection or of reactivation of lupus. Following a course of corticosteroid treatment the exacerbation resolved completely and the patient's neurological function continued to improve, resulting in net gain above pre-treatment for over 1 year follow-up without maintenance immunosuppression. Granulocytic invasion of the central nervous system represents a novel and possibly preventable cause of neurological complications during haematologic reconstitution.

Published
2006

Catalog

Books, media, physical & digital resources
See catalog results